THE THERAPEUTIC APPROACH TO DEEP VENOUS THROMBOSIS IN THE PATIENT WITH CIRRHOSIS OF THE LIVER

  • Irina Iuliana COSTACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Adriana ION “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • O. MITU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Amalia DARIE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irina GÎRLEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R. MIFTODE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • A. D. COSTACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • A. O. PETRIȘ “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

THE THERAPEUTIC APPROACH TO DEEP VENOUS THROMBOSIS IN THE PATIENT WITH CIRRHOSIS OF THE LIVER (Abstract): Venous thromboembolism is considered a very rare event in patients with liver cirrhosis, thus explaining unpredictable outcome. This may be due to the severe liver disease profoundly affecting coagulation. Patients with cirrhosis also have a reduction in anticoagulant proteins so their coagulative situation is characterized by a new balance of pro- and anticoagulation factors, defined as “rebalanced hemostasis”. Starting from the existing data in the literature so far, we studied 8 male patients previously known with cirrhosis, who were hospitalized with deep vein thrombosis (DVT) in the lower limbs in the Cardiology Clinic. The therapeutic approach to deep venous thrombosis associated with liver cirrhosis raises some issues related to the particular bleeding risk in this category of patients. DVT is not a rare condition in cirrhosis. The diagnosis of liver cirrhosis had been previously confirmed and justified by the presence of medical records at admission, and the diagnosis of DVT was based on clinical symptoms of DVT and confirmed using Duplex Doppler ultrasonography criteria for DVT.  Viral etiology of cirrhosis was predominant and diabetes mellitus was the only variable that was significantly associated with the presence of DVT. It is important though to consider, that serum albumin level of less than 3 mg/dL tended to be a risk factor. Our results coincide with those reported in the studied literature. The treatment unanimously accepted so far, initially with low-molecular-weight heparin (for 7-10 days) continued with Acenocumarol is adequate, with a low risk of bleeding. The precise mechanisms of hypercoagulability and thrombosis in cirrhosis are not well known and need further investigation.

Author Biographies

Irina Iuliana COSTACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

Adriana ION, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

O. MITU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

Amalia DARIE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

Irina GÎRLEANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

R. MIFTODE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

A. D. COSTACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

A. O. PETRIȘ, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi

References

1. Lesmana A, Rinaldi C, Sri Inggriani, Cahyadinata L, Laurentius A. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition? Hepatol Int 2010; 4(1): 433-438.
2. Leonard F, De Maria N, Villa E. Anticoagulation in cirrhosis: a new paradigm? Clinical and Molecular Hepatology 2017; 23: 13-21.
3. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107(Suppl I): 9-16.
4. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
5. NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2: 2156-2161.
6. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
7. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008; 47: 1384-1393.
8. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coag-ulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528.
9. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V, Forner M J. Venous thromboembo-lism and liver cirrhosis. Rev Esp Enferm Dig 2008; 100: 259-262.
10. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-1149.
11. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pul-monary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012-3017.
12. Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101.
13. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010; 8: 800-805.
14. Calborean V, Gheorman V, Istrătoaie O, et al. QT interval analysis in patients with chronic liver disease. Rev. Chim. (Bucharest) 2018; 69(5): 1134-1138.
15. Calborean V, Miscoci SA, Istrătoaie O, et al. Correlation Between Liver Cirrhosis and Risk of Cardiac Arrhythmias. Rev. Chim. (Bucharest) 2018; 69(6): 1527-1532.
16. Gîrleanu I, Alexandrescu DM, Petriș AO, Costache II. Barriers of antiaggregant treatment. Rev Med Chir Soc Med Nat Iasi 2014; 118(2): 333-338.
Published
2018-10-02
Section
INTERNAL MEDICINE - PEDIATRICS